NCT06660563

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the recommended phase 2 regimen (RP2R) for JNJ-80948543 in combination with JNJ-75348780 (Part 1: Dose Escalation) and to further assess the safety of JNJ-80948543 at the RP2R in combination with JNJ-75348780 (Part 2: Dose Expansion).

Conditions

• Lymphoma, Non-Hodgkin

Interventions

Type	Name	Description
DRUG	JNJ-80948543	JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.
DRUG	JNJ-75348780	JNJ-75348780 will be administered as SC injection.

Timeline

• Start date: 2024-10-22
• Primary completion: 2026-09-07
• Completion: 2026-09-21
• First posted: 2024-10-28
• Last updated: 2026-04-13

Locations

11 sites across 4 countries: Australia, Spain, Taiwan, United Kingdom

Regulatory

• FDA-regulated drug study